Effects of a Healthy Lifestyle Program on Health Outcomes in Older Adults
Prospective Study on Effects of a Healthy Lifestyle Program on Health Outcomes in Older Adults.
Medical condition or disease under investigation : Quantitative and qualitative aspects of sleep, quality of life, functional ability and well-being in older adults (>55years)
Purpose of clinical trial : To study the prospective effects of a healthy lifestyle program on quantitative and qualitative aspects of sleep, quality of life, functional ability and well-being in older adults.
Primary objective : Measure the effects of the intervention on quantitative and qualitative aspects of sleep
Secondary objective (s) : Measure the effects of the intervention on physical activity, quality of life, functional ability and well-being Social identity and leadership, social support and motivation
Trial Design : Intervention study : controlled before-and-after study
Sample Size : total sample size : 1.000 participants
Summary of eligibility criteria : Older adults aged above 55years
Included in intervention group : adults who are participating in the healthy lifestyle promotion program 'Lekker Actief', organized by OKRA
Included in control group : waitlist controls or controls (adults, members of OKRA, not participating in the health promotion program 'Lekker Actief')
Maximum duration of treatment of a subject :
- Start of Health promotion program 'Lekker Actief' : September 2018
- Measurements with accelerometers will start prior to the health promotion program 'Lekker Actief' : July 2018
- End of Health promotion program 'Lekker Actief' : December 2019
- Duration of Health promotion program 'Lekker Actief': 12 weeks
- Maximal duration : July 2018-December 2019
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This trial will consist of 3 visits : Pretest and posttest.
Pretest measurements (week 0)
o Accelerometry : a subsample of participants form intervention and control groups (n=400) will be asked to wear an accelerometer (type GT3X) during 7 entire days prior to baseline measurements. (Timing : July 2018-July 2019)
o Baseline measurements : during the start up moment of the program all participants from intervention and control groups will be asked : (Timing : July 2018-July 2019)
- To fill out the self-reported questionnaire (survey) : the survey is composed of existing validated scales : IPAQ, PSQI, SF-12, WEMWBS, HAQ-DI. (references of validated scales are provided in the 'outcome measures' section)
- To perform a walk test over 20 meters in order to determine the individual stride length
- To perform a 6 minute walking test in order to self-report perceived exertion and physical fitness (by Borg Scale) and to determine the individual entry level of the program (entry levels vary between 1-12)
- To wear the Pedometer (Omron® Walking Style one 2.0) on a daily basis and register the amount of daily steps in their personal registration forms
Posttest measurements (week 12)
- Accelerometry : a subsample of participants form intervention and control groups (n=400) will be asked to wear an accelerometer (type GT3X®) during 7 days prior to posttest measurements. (Timing : September 2018 - December 2019)
- Posttest measurements : at the end of the program all participants will be asked :
(Timing : September 2018 - December 2019)
- To fill out the self-reported questionnaire (survey). In addition to the pretest questionnaire, the validated scales ILI, Mael and Ashford (1992) and BREQ-3 will be added and will be filled out only by participants of the intervention groups
- To perform a 6 minute walking test in order to self-report perceived exertion and physical fitness (by Borg Scale)
- To inform the investigators on the amount of daily steps (measured with pedometer type : Omron® Walking Style one 2.0) during the 12 week program o Focus groups : a subsample will be invited to take part in focus groups. During these focus groups, participants will be encouraged to discuss the program and possible effects in small groups (5 participants per group). A semi-structured interview guide will be used to guide the discussions.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Flanders
-
Leuven, Flanders, Belgio, 3000
- KULeuven
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-aged 55+ years
Exclusion Criteria:
-Participants who are physically unable to participate in weekly meetings (PAR-Q : Physical activity readiness scale) (Thomas et al., 1992)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Intervention Group
12 week intervention
|
Participants (intervention group) are following a 12 week health promotion program.
They will count daily steps by pedometers and participate in weekly organised walks (within socio-cultural organisation)
Altri nomi:
|
|
Nessun intervento: Control Group
No walking program
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in sleep
Lasso di tempo: Pretest (week 0), posttest (week 12) and follow up (month 15)
|
Change in quantity of sleep : measured in minutes and hours by accelerometry and self-reported questionnaires (PSQI : Pittsburgh Sleep Quality Index (PSQI)) Change in quality of sleep : measured by self-reported questionnaire (PSQI)
|
Pretest (week 0), posttest (week 12) and follow up (month 15)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in objectively perceived physical activity
Lasso di tempo: Pretest (week 0), posttest (week 12) follow up (month 15)
|
Quantity : measured in minutes and hours by accelerometry
|
Pretest (week 0), posttest (week 12) follow up (month 15)
|
|
Change in subjectively perceived physical activity
Lasso di tempo: Pretest (week 0), posttest (week 12) follow up (month 15)
|
Quantity : measured by self-reported questionnaires (IPAQ : International Physical Activity Questionnaire)
|
Pretest (week 0), posttest (week 12) follow up (month 15)
|
|
change in quality of life
Lasso di tempo: Pretest (week 0), posttest (week 12) follow up (month 15)
|
measured by self-reported questionnaire (SF-12 : Short Form Health Survey)
|
Pretest (week 0), posttest (week 12) follow up (month 15)
|
|
change in functional ability
Lasso di tempo: Pretest (week 0), posttest (week 12) follow up (month 15)
|
measured by self-reported questionnaire (HAQ-DI : Health Assessment Questionnaire)
|
Pretest (week 0), posttest (week 12) follow up (month 15)
|
|
change in wellbeing
Lasso di tempo: Pretest (week 0), posttest (week 12) follow up (month 15)
|
well-being : measured by self-reported questionnaire (WEMWBS : Warwick-Edinburgh Mental Well-being scale)
|
Pretest (week 0), posttest (week 12) follow up (month 15)
|
|
Social identity and leadership
Lasso di tempo: Pretest (week 0), posttest (week 12)
|
measured by self-reported questionnaire (ILI : Identity Leadership Inventory)
|
Pretest (week 0), posttest (week 12)
|
|
motivation
Lasso di tempo: Pretest (week 0), posttest (week 12)
|
measured by self-reported questionnaire (BREQ3 : Behavioural Regulation In Exercise Questionnaire)
|
Pretest (week 0), posttest (week 12)
|
|
Social support
Lasso di tempo: Pretest (week 0), posttest (week 12)
|
measured by self-reported questionnaire (De Bourdeaudhuij & Salis, 2002)
|
Pretest (week 0), posttest (week 12)
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Julie Vanderlinden, phds, KU Leuven
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- Lekker Actief
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Periodo di condivisione IPD
Criteri di accesso alla condivisione IPD
Tipo di informazioni di supporto alla condivisione IPD
- Protocollo di studio
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .